As featured in Forbes
In a recent Forbes article, Robert Zambon, ConcertAI’s Vice President of Product, Clinical Solutions, discusses what HHS’s new SURPASS initiative could mean for the future of drug development. By working to reduce barriers across the development process, SURPASS has the potential to help promising and personalized therapies reach patients sooner—particularly those designed for smaller, more targeted populations. Read the full article to learn more about the opportunity and what it could mean for the industry.